REGISTER
MedJ at ESMO 2025 with Dr. Richard S. Finn
This topic gains urgency because MedJ at ESMO 2025 with Dr. Richard S. Finn affects both outcomes and management. It distills the central data on ESMO, UCLA, USA into a clear account of the article's most important conclusions.

Richard S. Finn, UCLA Medical Center, USA

Provided an on-site interpretation of the IMbrave152 study at ESMO: A new breakthrough in first-line treatment for liver cancer! The triple-therapy regimen significantly improved overall survival (OS) and progression-free survival (PFS), with a favorable safety profile, poised to reshape the treatment landscape for advanced hepatocellular carcinoma (HCC).

0
0
Loading